依库珠单抗治疗儿童非典型溶血尿毒综合征的临床分析
该病例系列研究回顾性纳入10例接受依库珠单抗治疗的儿童非典型溶血尿毒综合征患儿,评估疗效与安全性并探索停药策略。治疗4周后所有患儿摆脱透析、9例肾功能恢复正常,6例经医患共同决策停药后随访未见复发,安全性良好。
要点
- 依库珠单抗治疗4周后全部患儿摆脱透析,9例肾功能恢复正常。
- 6例经医患共同决策停药,停药后随访139(118,440)d无复发。
- 治疗中仅1例出现轻度肢体疼痛自行缓解,无其他不良反应。
核心结论
- 依库珠单抗治疗儿童非典型溶血尿毒综合征可明显改善肾功能、减少肾衰竭发生,且安全性高、不良反应少。
- 可遵循医师及患者共同决策模式,依据患儿病情及家庭经济情况合理选择停药时间。
研究设计与样本
- 病例系列研究,回顾性收集2024年3月至2025年9月郑州大学附属儿童医院住院并接受依库珠单抗治疗的10例非典型溶血尿毒综合征患儿临床资料。
- 收集内容包括基本信息、实验室检查、基因检测、用药过程、停药及停药后随访(截至2025年9月)情况。
主要发现
- 10例中男7例、女3例,起病年龄61.0(16.8,79.8)月龄;7例补体C3下降,3例抗补体因子H抗体升高。
- 全部患儿行基因检测,3例存在明确致病性基因变异:CFH基因杂合变异、CFHR1与CFHR3基因纯合缺失变异、DGKE基因杂合变异。
- 从出现临床症状至启动依库珠单抗治疗的延迟给药时间为7.5(5.0,10.5)d。
- 治疗前估算肾小球滤过率为58.0(31.8,64.0)ml/(min·1.73 m²);治疗4周后所有患儿摆脱透析,9例肾功能恢复正常。
- 启动治疗后血小板恢复正常所需时间为11.5(7.5,17.5)d;6例停药者持续用药总时间117(53,155)d,停药后随访139(118,440)d,0例复发,5例肾功能恢复正常、1例进入慢性肾脏病2期。
关键数值与推荐
- 延迟给药时间定义为从出现临床症状至启动依库珠单抗治疗的时间,本组为7.5(5.0,10.5)d。
- 停药遵循医师及患者共同决策模式,6例停药者持续用药总时间为117(53,155)d。
- 全部患儿用药前无四价脑膜炎球菌疫苗接种史,因病情危急均口服阿奇霉素预防感染,无患儿出现脑膜炎球菌感染。
临床怎么用
- 对儿童非典型溶血尿毒综合征可考虑使用依库珠单抗以改善肾功能、减少肾衰竭。
- 停药时机可依据患儿病情及家庭经济情况,通过医师及患者共同决策模式合理选择。
- 用药前无四价脑膜炎球菌疫苗接种史者,因病情危急可口服阿奇霉素预防感染并监测脑膜炎球菌感染。
局限性
- 本研究为单中心回顾性病例系列研究,样本量10例,证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficacy and safety of eculizumab, a terminal complement inhibitor, in the treatment of pediatric atypical hemolytic uremic syndrome (aHUS), and explore strategies for treatment discontinuation. Methods: This was a case series study. Clinical data of the 10 children diagnosed with aHUS who were hospitalized and treated with eculizumab at Children's Hospital affiliated to Zhengzhou University between March 2024 and September 2025 were retrospectively collected. The data included demographic characteristics, laboratory findings, genetic test results, medication process and drug discontinuation status as well as follow up (till September 2025) after drug withdrawal, etc. The clinical features and prognosis of these patients were summarized. Results: Ten aHUS children included 7 males and 3 females, with an onset age of 61.0 (16.8, 79.8) months. Decreased complement C3 levels were observed in 7 patients, and elevated anti-factor H antibodies in 3. Genetic testing was performed in all patients and identified pathogenic variants in 3 patients: heterozygous CFH mutation, homozygous CFHR1 and CFHR3 deletions, and heterozygous DGKE mutation. The time from symptom onset to eculizumab initiation (defined as delayed administration time) was 7.5 (5.0, 10.5) d. Before treatment, the estimated glomerular filtration rate was 58.0(31.8,64.0)ml/(min·1.73 m²). After 4 weeks of eculizumab therapy, all patients were free from dialysis, and 9 cases achieved normal renal function. Platelet counts normalized after 11.5 (7.5, 17.5) d. Based on physician-patient shared decision-making model, 6 patients discontinued eculizumab, with a treatment duration of 117(53, 155) d. During a follow-up of 139(118, 440) d post-discontinuation, no relapses occurred. Five regained normal renal function, and 1 progressed to stage 2 chronic kidney disease. One patient experienced self-resolved mild limb pain during the treatment, and no other adverse events were observed. None of the children had a history of vaccination with the quadrivalent meningococcal vaccine before treatment. Due to the critical condition, all patients received oral azithromycin for infection prophylaxis, and no case of meningococcal infection occurred. Conclusions: Eculizumab can significantly improve renal function, reduce the incidence of renal failure in the treatment of pediatric atypical hemolytic uremic syndrome and is associated with high safety and few adverse reactions. The decision on treatment discontinuation can be made following the physician-patient shared decision-making model, with the timing reasonably chosen based on the patient's clinical condition and family financial status. 目的: 总结终末补体抑制剂依库珠单抗治疗儿童非典型溶血尿毒综合征的有效性、安全性,并对依库珠单抗的停用时机进行初步探索。 方法: 病例系列研究。收集2024年3月至2025年9月在郑州大学附属儿童医院住院且应用依库珠单抗治疗的10例非典型溶血尿毒综合征患儿临床资料,包括基本信息、实验室检查结果、基因检测结果、用药过程、停药及停药后随访(截至2025年9月)情况等,总结其临床特征及预后。 结果: 10例非典型溶血尿毒综合征中,男7例、女3例;起病年龄61.0(16.8,79.8)月龄;7例存在补体C3下降;3例抗补体因子H抗体升高;全部患儿均进行了基因检测,3例存在明确致病性基因,分别为CFH基因杂合变异、CFHR1与CFHR3基因纯合缺失变异和DGKE基因杂合变异。从出现临床症状至启动依库珠单抗治疗的时间(称为延迟给药时间)为7.5(5.0,10.5)d;启动依库珠单抗治疗前患儿估算肾小球滤过率为58.0(31.8,64.0)ml/(min·1.73 m2),治疗4周后所有患儿摆脱透析,9例肾功能恢复正常;启动依库珠单抗治疗后所有患儿血小板恢复正常,所需要的时间为11.5(7.5,17.5)d;遵循“医师及患者共同决策模式”,其中6例已停用依库珠单抗治疗,患儿持续用药总时间为117(53,155)d;截至随访终点停药后随访时间为139(118,440)d,0例复发;5例肾功能恢复正常,1例进入慢性肾脏病2期;治疗过程中1例患儿出现肢体疼痛,程度较轻,自行缓解,其他患儿未发现用药不良反应;全部患儿用药前无四价脑膜炎球菌疫苗接种史,因病情危急,均口服阿奇霉素预防感染,无患儿出现脑膜炎球菌感染。 结论: 依库珠单抗治疗儿童非典型溶血尿毒综合征可明显改善患儿肾功能、减少肾衰竭发生,且安全性高,不良反应少;可遵循“医师及患者共同决策模式”,依据患儿病情及家庭经济情况合理选择停药时间。.
引用
- Zhang YX, Liu P, Liu YJ, et al. [Clinical analysis of eculizumab in the treatment of atypical hemolytic uremic syndrome in children]. Zhonghua Er Ke Za Zhi. 2026. PMID: 41986268. doi:10.3760/cma.j.cn112140-20251117-01035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。